Commercial Information Circulars
24-hour hotline : 23 922 922
e-mail address : enquiry@tid.gov.hk
Ref. : EIC 631/2/5
EIC 631/2/7
10 April 2018
Dear Sirs,
Commercial Information Circular No. 338/2018
The Mainland of China : Opinions on Reforming and Improving the Supply Assurance and Utilization Policies of Generic Drugs
The General Office of the State Council of the People's Republic of China issued on 21 March 2018 the "Opinions on Reforming and Improving the Supply Assurance and Utilization Policies of Generic Drugs". Amongst others, eligible generic drugs companies would enjoy pre-tax deductions for research and development expenses (in developing new technologies, new products and new processes) when calculating corporate income taxes. Also, the corporate income tax rate for generic drugs companies (if being identified as high and new technology enterprises) would be lowered to 15% . Please refer to the Appendix (pdf format) for the opinions (available in Chinese only).
ENQUIRIES
2.If you have any questions on the content of the document mentioned in this circular, please contact the issuing authority of the Mainland of China direct. For other questions on this circular, please contact Mainland Branch (I) (tel: 2398 5444) of the Department.
Yours faithfully,
(Calvin CHOY)
for Director-General of Trade and Industry
Note: While every effort is made to ensure the accuracy of the above information, the Department cannot guarantee this to be so and will not be held liable for any reliance placed on the same.